Clovis Oncology Inc. (NASDAQ:CLVS) shares were down 2.4% during trading on Thursday . The company traded as low as $14.45 and last traded at $14.66, with a volume of 617,159 shares traded. The stock had previously closed at $15.02.

A number of research analysts have recently commented on CLVS shares. Stifel Nicolaus reiterated a “buy” rating and set a $30.00 price target on shares of Clovis Oncology in a report on Tuesday, April 12th. Janney Montgomery Scott restated a “buy” rating on shares of Clovis Oncology in a research report on Wednesday, April 13th. Zacks Investment Research upgraded Clovis Oncology from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Thursday, April 14th. Vetr cut Clovis Oncology from a “strong-buy” rating to a “buy” rating and set a $17.66 price objective on the stock. in a research report on Wednesday, May 25th. Finally, Mizuho restated a “hold” rating on shares of Clovis Oncology in a research report on Wednesday, April 13th. Seven analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $29.25.

The company’s market cap is $565.41 million. The firm’s 50 day moving average price is $14.76 and its 200 day moving average price is $18.53.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.39) by $0.22. During the same period last year, the firm earned ($1.86) earnings per share. Clovis Oncology’s revenue for the quarter was up NaN% compared to the same quarter last year. On average, equities analysts anticipate that Clovis Oncology Inc. will post ($8.00) EPS for the current fiscal year.

Several hedge funds have added to or reduced their stakes in CLVS. Oxford Asset Management boosted its stake in Clovis Oncology by 344.0% in the fourth quarter. Oxford Asset Management now owns 93,893 shares of the biopharmaceutical company’s stock worth $3,304,000 after buying an additional 72,748 shares during the last quarter. California State Teachers Retirement System boosted its stake in Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares during the last quarter. ProShare Advisors LLC boosted its stake in Clovis Oncology by 9.5% in the fourth quarter. ProShare Advisors LLC now owns 36,129 shares of the biopharmaceutical company’s stock worth $1,265,000 after buying an additional 3,125 shares during the last quarter. Trexquant Investment LP acquired a new stake in Clovis Oncology during the fourth quarter worth about $3,170,000. Finally, Rhumbline Advisers boosted its stake in Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares during the last quarter.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.